Utilization of Cancer Cell Line Screening to Elucidate the Anticancer Activity and Biological Pathways Related to the Ruthenium-Based Therapeutic BOLD-100.

Park, Brian J; Raha, Paromita; Pankovich, Jim; Bazett, Mark

Park, Brian J; Raha, Paromita; Pankovich, Jim; Bazett, Mark.

Afiliação

Park BJ; Bold Therapeutics Inc., 422 Richards St, Suite 170, Vancouver, BC V6B 2Z4, Canada.
Raha P; Bold Therapeutics Inc., 422 Richards St, Suite 170, Vancouver, BC V6B 2Z4, Canada.
Pankovich J; Bold Therapeutics Inc., 422 Richards St, Suite 170, Vancouver, BC V6B 2Z4, Canada.
Bazett M; Bold Therapeutics Inc., 422 Richards St, Suite 170, Vancouver, BC V6B 2Z4, Canada.

Cancers (Basel) ; 15(1)2022 Dec 21.

Article em En | MEDLINE | ID: mdl-36612025

Palavras-chave

BOLD-100; cancer therapeutics; cell screening; ribosomes; ruthenium

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google